• Hypertrophic Cardiomyopathy (HCM)
  • Eyecare
  • Urothelial Carcinoma
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

September FDA Pipeline


New combinations

New combinationsVytorin

Ezetimibe and simvastatin


Cost. The ezetimibe/simvastatin combination tablet will be priced at $2.34 per dose for all doses, according to the manufacturer.

New indicationsAldara

Imiquimod cream, 5%



Atazanavir (Reyataz, Bristol-Myers Squibb) was approved for use with low-dose ritonavir (Norvir, Abbott) in treatment-experienced HIV-infected patients.

FDA approved levofloxacin tablets/injection and levofloxacin in 5% dextrose injection (Levaquin, Johnson & Johnson) to treat multi-drug resistant strains of Streptococcus pneumoniae in community-acquired pneumonia (CAP).

FDA approved lansoprazole (Prevacid, TAP Pharmaceutical Products) for the short-term treatment of symptomatic gastroesophageal reflux disease (GERD) and erosive esophagitis in adolescent patients aged 12 to 17 years. Also approved was a delayed-release, orally disintegrating tablet formulation of lansoprazole (Prevacid SoluTab, TAP Pharmaceutical Products), which can be administered via an oral syringe or nasogastric tube.

Intradermal botulinum toxin type A (Botox, Allergan) was approved for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents.

FDA approved additional efficacy labeling for quetiapine (Seroquel, AstraZeneca). The data demonstrated that after 12 weeks, approximately two-thirds of patients receiving quetiapine as monotherapy achieved remission. The new label includes safety and efficacy data for mania associated with bipolar disorder extending up to Week 12.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.